VTYX vs. RNAC, ALT, MREO, PROK, ERAS, AKBA, KALV, ORGO, ETON, and SAGE
Should you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Cartesian Therapeutics (RNAC), Altimmune (ALT), Mereo BioPharma Group (MREO), ProKidney (PROK), Erasca (ERAS), Akebia Therapeutics (AKBA), KalVista Pharmaceuticals (KALV), Organogenesis (ORGO), Eton Pharmaceuticals (ETON), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry.
Ventyx Biosciences vs.
Ventyx Biosciences (NASDAQ:VTYX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
97.9% of Ventyx Biosciences shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 18.2% of Ventyx Biosciences shares are held by insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Ventyx Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 502.41%. Cartesian Therapeutics has a consensus price target of $42.86, indicating a potential upside of 118.55%. Given Ventyx Biosciences' higher possible upside, equities analysts clearly believe Ventyx Biosciences is more favorable than Cartesian Therapeutics.
In the previous week, Ventyx Biosciences had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Ventyx Biosciences and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.00 beat Ventyx Biosciences' score of -0.04 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.
Ventyx Biosciences has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Ventyx Biosciences' return on equity.
Ventyx Biosciences has higher earnings, but lower revenue than Cartesian Therapeutics. Ventyx Biosciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cartesian Therapeutics received 3 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 94.44% of users gave Cartesian Therapeutics an outperform vote while only 46.97% of users gave Ventyx Biosciences an outperform vote.
Ventyx Biosciences has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.
Summary
Cartesian Therapeutics beats Ventyx Biosciences on 9 of the 15 factors compared between the two stocks.
Get Ventyx Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ventyx Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:VTYX) was last updated on 2/21/2025 by MarketBeat.com Staff
Free VTYX Stock Alerts